



PRESS RELEASE

Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC

The Company will secure over 2 Million in assets as well as as personnel necessary for clinical trials in latest acquisition

Melbourne, FL – Branded Legacy ([OTC.PK: BLEG](#)), Inc., a leading BioTech holdings company, announced today the signed letter of intent to purchase Sycamore BioPharma, LLC, an established developer of plant based pharmaceuticals. The strategic move aligns with Branded Legacy's commitment to expanding its portfolio in the biotech sector and further solidifies its position as a key player in the industry.

Sycamore BioPharma has garnered a reputation as a prolific product developer, offering a meticulously curated line of wellness solutions ranging from gummies to compression sleeves and pain-relieving topical creams. They currently possess over 2 million in assets and over \$500,000 in high quality ready to sell inventory. With a commitment to quality, authenticity, and a passion for natural ingredients, Sycamore BioPharma has become a trusted name in the industry.

"Branded Legacy is excited to welcome Sycamore BioPharma into our family of companies," said David Oswald, CEO at Branded Legacy, Inc. "This strategic acquisition will not only complement our existing portfolio but also reinforces our commitment to providing innovative solutions for wellness and health. Sycamore BioPharma's expertise in botanical extracts, sustainable plant-based products, and natural Active Pharmaceutical Ingredients perfectly aligns with our vision for the future of bio-tech."

The collaboration between Branded Legacy and Sycamore BioPharma is poised to create synergies across various aspects of the business. Branded Legacy's web properties, brand management, and marketing teams will work in tandem with Sycamore BioPharma to maximize the reach and impact of their innovative wellness solutions. This integration will enable a seamless exchange of ideas, expertise, and resources to enhance customer experiences and elevate both brands in the market. In addition Branded Legacy will add another PHD holding scientist, Dr. Mark Hamann, to its roster. This will not only bolster efforts in developing novel pharmaceuticals, but will also streamline the FDA approval process, especially with regards to clinical trials.



PRESS RELEASE

"Sycamore BioPharma has crafted a unique and high-quality product line, and we see immense potential in amplifying its reach through our branding, marketing, and sales channels," said Doug Holladay, CMO at Branded Legacy, Inc. "Our dedicated teams will work closely to integrate Sycamore BioPharma's offerings into our comprehensive strategy, ensuring that these exceptional wellness solutions reach a broader audience."

The acquisition will provide Sycamore BioPharma with access to Branded Legacy's extensive network, enabling the company to tap into new markets and demographics. The combined resources and expertise of both companies will enhance Sycamore BioPharma's ability to connect with consumers, build brand loyalty, and drive sales growth.

Sycamore BioPharma brings state-of-the-art extraction equipment to the table, further bolstering Branded Legacy's already robust extraction capabilities. This combined technological prowess will fuel advancements in product development, ensuring the delivery of superior, research-backed remedies that set new standards in the biotech industry. "We are thrilled to welcome Sycamore BioPharma into the Branded Legacy family. This strategic acquisition will greatly enhance our existing technological infrastructure. The addition of their high volume Critical CO2 extraction capabilities to our existing CO2 capacity is a crucial step in securing a major Kavalactone extraction and refinement contract. In turn we will employ our recently acquired topical and cosmetic packaging equipment as a huge cost saving measure to Sycamore BioPharm's operations. Together, our combined capabilities propel us to the forefront of innovation, ensuring the delivery of high-quality, scientifically-backed solutions that set new standards in the biotech industry." Said Joseph Holladay, Branded Legacy COO.

Branded Legacy, Inc. looks forward to the strategic collaboration with Sycamore BioPharma, aiming to drive innovation, improve customer experiences, and shape the future of the biotech industry. With a shared dedication to quality, authenticity, and a passion for wellness, the partnership between Branded Legacy and Sycamore BioPharma is poised to reshape the landscape of natural products processing and sustainable plant-based solutions.

This acquisition comes at a great time as Branded Legacy has recently signed several large white label manufacturing deals, ensuring throughput and creating a clear path to profitability.

For more information about Sycamore BioPharma, LLC, please visit: <https://sycamorebp.com/>



PRESS RELEASE

Original Copy of this Press Release:

<https://brandedlegacy.com/branded-legacy-inc-strengthens-position-in-biotech-industry-with-letter-of-intent-to-purchase-sycamore-biopharma-llc>

For media inquiries, please contact:

Investor Relations & Media Contact

Joe Holladay

Branded Legacy

Phone: 321-345-3565

Email: info@brandedlegacy.com

Website: <https://brandedlegacy.com/>

About Branded Legacy, Inc.:

Branded Legacy, Inc. (OTC: BLEG) is a diversified holdings company focused on the biotech sector. With a commitment to excellence and innovation, Branded Legacy specializes in the development and marketing of cutting-edge products and services. The company's diverse portfolio includes ventures in biotechnology, digital solutions, and wellness products, all aimed at enhancing the quality of life for its customers. Branded Legacy's strategic approach to growth involves identifying and integrating promising businesses and technologies that align with its mission to deliver sustainable, high-quality products and services.

Safe Harbor Statement on Forward-Looking Language:

This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. The company disclaims any



PRESS RELEASE

intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.